3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Breast Neoplasms
23
Ovarian Neoplasms
20
Triple Negative Breast Neoplasms
12
Neoplasms
9
Neoplasm Metastasis
9
Fallopian Tube Neoplasms
9
Pancreatic Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Glioblastoma
5
Astrocytoma
5
Stomach Neoplasms
4
Small Cell Lung Carcinoma
4
Gliosarcoma
4
Colonic Neoplasms
4
Brain Neoplasms
4
Recurrence
3
Rectal Neoplasms
3
Prostatic Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Melanoma
3
Lymphoma
3
Lung Neoplasms
3
Leukemia, Myelomonocytic, Chronic
3
Leukemia, Myeloid, Acute
3
Carcinoma, Ovarian Epithelial
3
Breast Neoplasms, Male
3
Uterine Cervical Neoplasms
2
Thrombocythemia, Essential
2
Testicular Neoplasms
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Interventions
Carboplatin
8
Trastuzumab
6
Docetaxel
5
pembrolizumab
4
Paclitaxel
4
Oxaliplatin
4
Fluorouracil
4
Cytarabine
4
Cyclophosphamide
4
Azacitidine
4
pertuzumab
3
Radiotherapy
3
Epirubicin
3
Cisplatin
3
Chemoradiotherapy
3
Capecitabine
3
130-nm albumin-bound paclitaxel
3
venetoclax
2
toripalimab
2
sargramostim
2
olaparib
2
durvalumab
2
cc-486
2
Tretinoin
2
Surgical Procedures, Operative
2
Standard of Care
2
Pemetrexed
2
Observation
2
Monatide (IMS 3015)
2
Metformin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Pathologic Complete Response
×
veliparib
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled